Nucleoli and argyrophil nucleolus organizer regions (AgNORs) of cells of the megakaryocytic line in the rat

The main maturation stages of Norway rat megakaryocytic series, megakaryoblasts and mature megakaryocytes, stained by silver for demonstration of argyrophil nucleolus organizer regions (AgNORs) were investigated to provide basic information on the number of nucleoli and interphasic AgNORs in these cells. The results showed that megakaryoblasts as well as mature megakaryocytes possess numerous nucleoli; their number and also the number of AgNORs is significantly higher in less mature than in more mature cells. The number of AgNORs in megakaryocytes of the Norway rat and man are virtually the same, although the numbers of nucleolar organizers per haploid chromosome set differ markedly. This fact leads to the conclusion that the number of interphasic AgNORs depends on the function and metabolic state of the cell rather than on the number of nucleolar organizers.     

Spot welding of metal laminated composites

Composite materials of steel sheets joined by interlayers of zinc or lead- tin, show very good impact and corrosion resistance properties. Resistance spot-weld characteristics of these composite materials made of steel sheets and non-ferrous metals have been tested. Spot welds of composites with both zinc and lead- tin interlayers present good behaviour in peeling tests. Shear tests of the welds also show very high strength, probably as a consequence of simultaneous brazing because of the alloyed layer of non-ferrous material around the weld spot. This good welding behaviour enhances the possibilities of application of this composite.     

Cloning and sequencing of a tpr-met oncogene cDNA isolated from MNNG-transformed human XP fibroblasts

A rearranged tpr-met oncogene was identified in a MNNG-transformed human Xeroderma pigmentosum (XP) cell line (ASKMN). A 2016 bp cDNA was cloned and sequenced, disclosing an ORF with a coding capacity for a 523 aa protein. The sequence of this tpr-met cDNA was very similar to that previously reported in another human MNNG-transformed cell line (MNNG-HOS).     

Probabilistic linear models for multiresolution estimation in gray-level images

A multiresolution analysis of digital gray-level images is presented. A gray-level multi-scale framework is determined from two main assumptions: the gray scale is binary at the finest spatial resolution, and the gray levels of composed regions are obtained additively. In order to interrelate the gray-level histograms of the same image at different resolutions, probabilistic linear models are developed, which are then applied for estimation. Linear-optimization theory is used as a way of constructing such models. A general procedure for image processing is sketched, based on gray-level estimation. A versatile algorithm for nonlinear filtering is derived. Some examples of prospective applications are given.This work was partially supported by grant TIC91-646 from the DGYCIT of the Spanish Government.     

Hemocompatibility in hemodialysis and erythropoietin therapy

Two studies designed to investigate the effect of recombinant human erythropoietin (rHuEPO) treatment of anemia in chronic dialysis patients on hemocompatibility were conducted. Study 1, whose main aim was to establish whether treatment with rHuEPO enhances coagulation activation during dialysis, included 15 patients before rHuEPO therapy at a mean hematocrit (HCT) of 22.3% and then during therapy at a HCT of 29.3%. The plasma concentrations of the thrombin-antithrombin III complex were not higher during rHuEPO therapy than before it when performing hemodialysis with a Cuprophan membrane. No significant difference was demonstrated either in the values of activated clotting times (Hemochron), thrombocyte or white blood cell counts (Coulter S+II), or in plasma C5a concentrations (ELISA) established during dialysis sessions before and during rHuEPO therapy. In Study 2, which focused primarily on the question of whether or not rHuEPO therapy increases thrombocyte activation during hemodialysis, 8 patients on chronic dialysis were examined both before therapy at a mean HCT value of 22.1% and during rHuEPO therapy at a HCT of 31.5%, invariably during dialysis with either a Cuprophan or polyacrylonitrile (AN69HF) membrane. The plasma concentrations of beta-thromboglobulin (ELISA) did not differ between the examinations made during rHuEPO and before rHuEPO therapy; however, statistically significant differences were found between dialysis sessions involving Cuprophan and AN69HF membranes. No significant difference between examination before and during rHuEPO was demonstrated in activated clotting time nor thrombocyte and white blood cell counts in this study either. The authors conclude that rHuEPO therapy does not enhance coagulation activation during hemodialysis, does not have an effect on thrombocyte activation, and does not influence complement activation and changes in white blood cell counts.